Cumberland Pharmaceuticals Q3 Earnings Call Highlights
Cumberland Pharmaceuticals reported third-quarter net income of $77.8 million, reflecting the sale of its commercial products to Apotex Health. The company also outlined plans to advance its lead drug candidate toward a regulatory submission for Duchenne muscular dystrophy-associated heart disease.
Why it matters — CPIX watchers may note both the reported income tied to the product sale and the company’s stated next step for its lead candidate.